Skip to main content

Table 4 Fisher’s exact test to evaluate the association between ABCC1 and other clinical factors

From: Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols

Covariate Score ABCC1 Negative ABCC1 Positive Fisher's ExactTest (2-Tail)
ABCG2 Negative 39 (79.6%) 10 (20.4%) .5227
Positive 22 (88%) 3 (12%)
Chemotherapy ABVD (R-ABVD & MOPP/ABVD) 20 (76.9%) 6 (23.1%) .8762
CVPP/ABDIC 15 (83.3%) 3 (16.7%)
NOVP 31 (81.6%) 7 (18.4%)
Radiotherapy No 17 (89.5%) 2 (10.5%) .3329
Yes 45 (77.6%) 13 (22.4%)
Bone marrow disease No 62 (79.5%) 16 (20.5%) 1.000
Yes 3 (100%) 0 (0%)
Stage IV disease No 53 (80.3%) 13 (19.7%) 1.000
Yes 13 (81.3%) 3 (18.8%)
Hemoglobin ≥105 g/l 58 (79.5%) 15 (20.5%) .6811
< 105 g/l 8 (88.9%) 1 (11.1%)
Albumin ≥ 40 g/l 35 (79.5%) 9 (20.5%) 1.000
< 40 g/l 23 (82.1%) 5 (17.9%)
WBC <15,000 per mm3 62 (79.5%) 16 (20.5%) .5814
≥15,000 per mm3 4 (100%) 0 (0%)
Lymphocytes < 600 per mm3 52 (80%) 13 (20%) 1.000
≥ 600 per mm3 11 (78.6%) 3 (21.4%)
Age ≥45 < 45 years 51 (78.5%) 14 (21.5%) .5028
≥ 45 years 15 (88.2%) 2 (11.8%)
Sex Female 26 (76.5%) 8 (23.5%) .5731
Male 40 (83.3%) 8 (16.7%)
IPS <3 51 (77.3%) 15 (22.7%) .2811
  ≥3 14 (93.3%) 1 (6.7%)